Home > Insider Trading > Filing (0001140361-13-034594)

Filing Details

Accession Number:: 0001140361-13-034594
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-08-29 16:40:32
Reporting Period:: 2013-08-27

Filing Date:: 2013-08-29
Accepted Time:: 2013-08-29 16:40:32
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1311596	Regado Biosciences Inc	RGDO	Pharmaceutical Preparations (2834)	030422069

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1189158	Sherrill P Neff	Cira Centre, 2929 Arch Street Philadelphia PA 19104		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.001 Per Share	Acquisiton	2013-08-27	399,201	$0.00	435,129	No	4	C	Indirect	See Footnote 6
Common Stock, Par Value $0.001 Per Share	Acquisiton	2013-08-27	273,468	$0.00	708,597	No	4	C	Indirect	See Footnote 6
Common Stock, Par Value $0.001 Per Share	Acquisiton	2013-08-27	465,252	$0.00	1,173,849	No	4	C	Indirect	See Footnote 6
Common Stock, Par Value $0.001 Per Share	Acquisiton	2013-08-27	48,362	$0.00	1,222,211	No	4	C	Indirect	See Footnote 6
Common Stock, Par Value $0.001 Per Share	Acquisiton	2013-08-27	71,810	$4.00	1,294,021	No	4	P	Indirect	See Footnote 6

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote 6
No	4	C	Indirect	See Footnote 6
No	4	C	Indirect	See Footnote 6
No	4	C	Indirect	See Footnote 6
No	4	P	Indirect	See Footnote 6

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock, Par Value $0.001 Per Share	Stock Option (right to buy)	Acquisiton	2013-08-27	17,964	$0.00	17,964	$4.00
Common Stock, Par Value $0.001 Per Share	Series B Preferred Stock	Disposition	2013-08-27	6,666,667	$0.00	399,201	$0.00
Common Stock, Par Value $0.001 Per Share	Series C Preferred Stock	Disposition	2013-08-27	4,566,908	$0.00	273,468	$0.00
Common Stock, Par Value $0.001 Per Share	Series D Preferred Stock	Disposition	2013-08-27	7,769,715	$0.00	465,252	$0.00
Common Stock, Par Value $0.001 Per Share	Series E Preferred Stock	Disposition	2013-08-27	807,652	$0.00	48,362	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
17,964	2023-08-27	No	4	A	Direct
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect

Footnotes

100% of the shares underlying the option will vest on the one-year anniversary of the date of grant.
The shares of Series B Preferred Stock had no expiration date and automatically converted upon the consummation of the initial public offering of Regado Biosciences, Inc. (the "Company") at a conversion ratio of 1 share of Series B Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
The shares of Series C Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series C Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
The shares of Series D Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series D Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
The shares of Series E Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series E Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
The reportable securities are directly held by Quaker BioVentures, L.P. ("Quaker"). Quaker BioVentures Capital, L.P. ("Quaker Capital LP") is the general partner of the Quaker. Quaker BioVentures Capital, LLC ("Quaker Capital LLC") is the general partner of Quaker Capital LP and has voting and dispositive power over the shares held by Quaker. Voting and investment determinations made by Quaker Capital LLC with respect to the shares held by Quaker are made by an investment committee of Quaker Partners Management, L.P., which committee includes P. Sherrill Neff (the "Reporting Person"), a member of the board of the directors of the Company. The Reporting Person disclaims beneficial ownership of the securities held by Quaker, except to the extent of his pecuniary interest therein.